Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process. Investors looking for stocks that can make dramatic gains often turn ...

Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...